Arena Pharmaceuticals, Inc. (ARNA): Price and Financial Metrics

Arena Pharmaceuticals, Inc. (ARNA)

Today's Latest Price: $42.00 USD

0.12 (-0.28%)

Updated Mar 31 8:00pm

Add ARNA to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 337 in Biotech

See all "A" rated Strong Buy stocks

ARNA Stock Summary

  • ARNA's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 8.03% of US stocks.
  • Over the past twelve months, ARNA has reported earnings growth of -482.68%, putting it ahead of merely 3.15% of US stocks in our set.
  • Revenue growth over the past 12 months for Arena Pharmaceuticals Inc comes in at 4,387.65%, a number that bests 99.68% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Arena Pharmaceuticals Inc, a group of peers worth examining would be PRQR, CYAD, PULM, VYGR, and SMMT.
  • Visit ARNA's SEC page to see the company's official filings. To visit the company's web site, go to
ARNA Daily Price Range
ARNA 52-Week Price Range

ARNA Stock Price Chart More Charts

ARNA Price/Volume Stats

Current price $42.00 52-week high $64.48
Prev. close $42.12 52-week low $32.95
Day low $41.03 Volume 869,000
Day high $43.39 Avg. volume 625,411
50-day MA $45.87 Dividend yield N/A
200-day MA $50.19 Market Cap 2.11B

Arena Pharmaceuticals, Inc. (ARNA) Company Bio

Arena Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing drugs to address unmet medical needs. The company was founded in 1997 and is based in San Diego, California.

ARNA Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:

We started the process of determining a valid price forecast for Arena Pharmaceuticals Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Arena Pharmaceuticals Inc ranked in the 86th percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 1326.67%. The most interesting components of our discounted cash flow analysis for Arena Pharmaceuticals Inc ended up being:

  • The company's debt burden, as measured by earnings divided by interest payments, is 107.01; that's higher than 93.96% of US stocks in the Healthcare sector that have positive free cash flow.
  • The business' balance sheet reveals debt to be 2% of the company's capital (with equity being the remaining amount). Approximately merely 8.06% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
  • ARNA's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 59.14% of tickers in our DCF set.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

Want more companies with a valuation profile/forecast similar to that of Arena Pharmaceuticals Inc? See CRHM, STAA, INCY, PETQ, and INBP.

ARNA Latest News Stream

Event/TimeNews Detail
Loading, please wait...

ARNA Latest Social Stream

Loading social stream, please wait...

View Full ARNA Social Stream

ARNA Price Returns

1-mo -5.83%
3-mo N/A
6-mo -7.18%
1-year -5.64%
3-year 187.67%
5-year -5.83%
YTD -7.53%
2019 16.61%
2018 14.66%
2017 139.23%
2016 -25.26%
2015 -45.24%

Continue Researching ARNA

Want to see what other sources are saying about Arena Pharmaceuticals Inc's financials and stock price? Try the links below:

Arena Pharmaceuticals Inc (ARNA) Stock Price | Nasdaq
Arena Pharmaceuticals Inc (ARNA) Stock Quote, History and News - Yahoo Finance
Arena Pharmaceuticals Inc (ARNA) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8113 seconds.